Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease

Advances in Supportive Care for Multiple Myeloma

(2017) Noopur S. Raje et al.   Journal of the National Comprehensive Cancer Network

A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity

(2014) H Eda et al.   LEUKEMIA

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma

(2013) Samantha Pozzi et al.   BONE

Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis

(2013) Martyn K. Robinson et al.   DRUG DISCOVERY TODAY

Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy

(2013) T Scullen et al.   LEUKEMIA

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

(2013) A J Jakubowiak et al.   LEUKEMIA

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

(2013) A Z Badros et al.   LEUKEMIA

Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases

(2013) E. Michael Lewiecki   Therapeutic Advances in Musculoskeletal Disease

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma

(2012) Sundar Jagannath et al.   Clinical Lymphoma Myeloma & Leukemia

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

(2012) M A Hurchla et al.   LEUKEMIA

Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation

(2012) N Giuliani et al.   LEUKEMIA

Sclerostin is overexpressed by plasma cells from multiple myeloma patients

(2011) Giacomina Brunetti et al.   Annals of the New York Academy of Sciences

Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma

(2011) Noopur Raje et al.   CLINICAL CANCER RESEARCH

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy

(2011) Evangelos Terpos et al.   INTERNATIONAL JOURNAL OF CANCER

New targets for intervention in the treatment of postmenopausal osteoporosis

(2011) E. Michael Lewiecki   Nature Reviews Rheumatology

Myeloma cells suppress osteoblasts through sclerostin secretion

(2011) S Colucci et al.   Blood Cancer Journal

Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression

(2010) G. R. Heiland et al.   ANNALS OF THE RHEUMATIC DISEASES

Guidelines for assessment of bone microstructure in rodents using micro-computed tomography

(2010) Mary L Bouxsein et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

(2010) S. Vallet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

(2009) M. Fulciniti et al.   BLOOD

Wnt signaling as a therapeutic target for bone diseases

(2009) Luke H Hoeppner et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma

(2009) N Raje et al.   LEUKEMIA

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

The pathogenesis of the bone disease of multiple myeloma

(2008) Claire M. Edwards et al.   BONE

Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis*

(2008) Xiaodong Li et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA